The institutional cluster is mixed but net bearish in dollar terms, with large holders trimming while smaller funds add. The Q2 earnings showed strong top-line growth but expanding losses, and the Alzheimer's agitation launch costs are weighing on profitability. Monitor next quarter for evidence that the Alzheimer's launch spend is translating into revenue acceleration.
Drugs in focus
AXSM drug pipeline →AXS-12
● Neutral Named in this fund cluster- Impact
- Phase
- Filed/PDUFA (NDA accepted; Phase 3 completed)
- Time to market
- NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
- Next catalyst
- PDUFA date · May 1, 2027 165d
What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $214.66entry
- T+1 · 3mo ago −0.46%α −1.15% · $213.68
- T+5 · 3mo ago +1.65%α +2.09% · $218.20
- T+20 · 2mo ago −1.65%α +0.25% · $211.12
- T+60 · 12d ago −39.53%α −34.42% · $129.80
How similar events traded
Executive Summary
Q2 2026 13F cluster for Axsome Therapeutics shows a mixed institutional picture: 9 smaller buyers added $24.4M in new positions, while 8 larger sellers trimmed $57.4M, led by Assenagon Asset Management ($35.1M trim) and Nuveen ($10.2M trim). The buying is concentrated among smaller asset managers and state pension funds, while the selling is dominated by larger institutional holders. This divergence, combined with the company's Q2 earnings report 2 days ago showing strong revenue growth (+46% YoY to $218.4M) but widening losses (-$51.3M net loss), suggests institutions are split on the risk/reward of the Alzheimer's agitation launch ramp versus escalating SG&A costs.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$18.5M
▲ Buyers (9)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Russell Investments Group | ADD | +69.6% | $14.8M | $8.8M |
| State Board Of Administration Of Florida | DOUBLED | +245.2% | $7.7M | $6.1M |
| Fifth Third Bancorp | ADD | +53.2% | $6.1M | $3.3M |
| Police & Firemen's Retirement System Of New | ADD | +74.5% | $4.8M | $2.9M |
| Imc-Chicago | ADD | +29.8% | $2.5M | $1.2M |
| Mml Investors Services | DOUBLED | +146.8% | $1.3M | $919.0K |
| Polen Capital Management | DOUBLED | +111.2% | $1.1M | $736.0K |
| Commonwealth Equity Services | ADD | +47.1% | $597.0K | $317.0K |
| Farther Finance Advisors | ADD | +76.4% | $126.0K | $76.0K |
▼ Sellers (8)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Assenagon Asset Management | TRIM | -47.5% | $146.4M | -$35.1M |
| Nuveen | TRIM | -43.4% | $56.7M | -$10.2M |
| Aberdeen Group | TRIM | -47.7% | $25.3M | -$6.2M |
| Walleye Capital | NEAR_EXIT | -95.1% | $5.9M | -$5.5M |
| Strs Ohio | NEAR_EXIT | -91.3% | $1.8M | -$1.6M |
| M&G | TRIM | -35.4% | $15.4M | -$987.2K |
| Citigroup | TRIM | -26.3% | $31.4M | $2.1M |
| Atria Investments | TRIM | -30.1% | $232.0K | $3.0K |
Key Facts
- 9 buyers added $24.4M in new positions; 8 sellers trimmed $57.4M
- Largest seller: Assenagon Asset Management trimmed 47.5% of its position, reducing by $35.1M
- Largest buyer: Russell Investments Group added $8.8M (+69.6% shares)
- State Board of Administration of Florida doubled its position (+245.2%, +$6.1M)
- Q2 2026 revenue grew 46% YoY to $218.4M, but net loss widened to $51.3M
- No insider open-market buying corroborates the institutional cluster
Financial Impact
Net institutional selling of ~$33.0M ($57.4M sold vs $24.4M bought). The largest single move was Assenagon's $35.1M trim, representing 0.3% of AXSM's $11.4B market cap.
Risk Factors
- Alzheimer's agitation launch costs may continue to pressure margins and delay profitability
- Larger institutional sellers (Assenagon, Nuveen, Aberdeen) may continue reducing positions
- No insider buying to confirm the bullish thesis from smaller buyers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-AXSM-2026-Q2 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Viewing Entry $214.66 to $218.20 ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers